Diana de Walt - 07 Apr 2026 Form 4 Insider Report for HOLOGIC INC (HOLX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Apr 2026, 17:23:25 UTC
Prior SEC filing
03 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mark W. Irving, attorney-in-fact for Ms. De Walt

Key filing fact

Diana de Walt filed Form 4 for HOLOGIC INC (HOLX) on 09 Apr 2026.

Key facts

  • This page summarizes Diana de Walt's Form 4 filing for HOLOGIC INC (HOLX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 09 Apr 2026, 17:23.

Change

  • Previous filing in this sequence was filed on 03 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002039767 Primary reporting owner

De Walt Diana

Relationship
SVP, Human Resources
Address
250 CAMPUS DRIVE, MARLBOROUGH
Signature
/s/ Mark W. Irving, attorney-in-fact for Ms. De Walt
Signature date
09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HOLX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-7,603
Change %
-100%
Price
Shares after
0
Date
07 Apr 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Diana de Walt is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").

Footnote F2

At the Effective Time, each time-vesting restricted stock unit award ("Company RSU") held by the reporting person granted before October 21, 2025 converted into the right to receive the Merger Consideration for each share of Company Common Stock underlying the Company RSU; and each Company RSU held by the reporting person granted after October 21, 2025 converted into, for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time, (i) an unvested award representing the right to receive a cash payment equal to the Cash Consideration, and (ii) an unvested award representing the right to receive cash payments equal to the payments to the holder of one CVR, if any, pursuant to the CVR agreement, in each case, subject to the terms applied to the corresponding Company RSU immediately prior to the Effective Time. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .